Huge opportunity for development of nanodrugs for wide variety of clinical indications

TORONTO and HAIFA, Israel, Feb. 14, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the "Company" or "NurExone"), a biopharmaceutical company, announced today the commencement of efforts to license its proprietary ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes. Exosomes, which have a natural affinity for inflamed tissues, deliver loaded therapeutic cargo to inflamed tissues or cells, creating a healing environment. Therapeutic cargo to be delivered is expected to include different types of small molecules including miRNA, siRNA, mRNA, lncRNA, peptides or even synthetic drugs.

The Company's ExoTherapy platform for exosome-based therapy production includes: (i) large-scale exosome production using the Company's dedicated bioreactor, (ii) synthesis of therapeutic cargo and (iii) processes to load the therapeutic cargo, creating nanodrugs. Scientific results and initiatives have demonstrated efficiency of the Company's large-scale production process, its effectiveness of the Company's proprietary small-interfering RNA ("siRNA") sequences as therapeutic cargo and the technology for loading therapeutic cargo into exosomes. The Company's proprietary loading technology is described in a recently published PCT application entitled "Compositions and Methods for Loading Extracellular Vesicles", WO/2023/233395.

Dr. Lior Shaltiel, CEO of NurExone, commented, "Exosomes have the potential to be the ultimate drug delivery system. A particularly essential component of being able to use exosomes is developing an efficient and simple process to load them with therapeutic active ingredients. Our team of researchers has innovated a proprietary technology for this purpose, for which we have also applied for a patent. ExoPTEN, for patients with acute spinal cord injuries, is being developed on our platform, and we expect great success through licensing our technology for other indications!".

According to Dr. Bat Ami Gotliv, the Company's intellectual property consultant, "The latest application discloses and claims novel compositions and methods for loading extracellular vesicles with active molecules conjugated to hydrophilic compounds such as carbohydrates or derivatives thereof. This platform assists in enriching EVs and specifically exosomes with active molecules, and therefore EVs with high concentrations of active molecules are obtained. The exosomes carry their selected chemical content inside cells, and can serve as an excellent drug delivery tool for drugs that need to penetrate cells' membrane and accumulate intracellularly".

About NurExone Biologic Inc.

NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The company's first product, ExoPTEN for acute spinal cord injury, was proven to recover motor and sensory functions in up to 75% of laboratory rats when administered intranasally. ExoPTEN has received Orphan Drug Designation from the FDA with first-in-human expected in 2025. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.

For additional information, please visit or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com

Dr. Eva Reuter
Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

FORWARD-LOOKING STATEMENTS

This press release contains certain forward-looking statements, including statements about the Company's future plans and intellectual property, the scientific and development and commercial activities to be carried out by the company, the efficient loading of exosomes, future potential manufacturing, clinical, licensing and marketing activities and the treatment of certain conditions. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company's early stage of development, lack of revenues to date, government regulation, market acceptance for its products, rapid technological change, dependence on key personnel, protection of the Company's intellectual property and dependence on the Company's strategic partners. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.